Press release
Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
- ARO-APOC3 achieved triglyceride reductions of 74-92% - ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35% - Company to host
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":"\n- ARO-APOC3 achieved triglyceride reductions of 74-92%\n\n- ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35%\n\n- Company to host upcoming KOL webinars on ARO-APOC3 and ARO-ANG3\n\n PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2020.\n\nJavier San Martin, M.D., chief medical officer at Arrowhead, said: “The data presented at AHA on our cardiometabolic pipeline continue to show strong and consistent response across a range of lipid parameters. There remains significant residual cardiovascular risk despite recent scientific advances, and we believe that our cardiometabolic pipeline has the ability to target new therapeutic targets and address multiple lipid parameters associated with increased cardiovascular risk.”\n\nCopies of the following presentations may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website:\n\nTitle: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia\nAuthors: Gerald F. Watts, et al.\nSession: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD\n\nTitle: Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia\nAuthors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al.\nSession: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD\n\nTitle: Safety, Tolerability and Efficacy of Single-Dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects with Elevated Lp(a)\nAuthors: Michael J. Koren, et al.\nSession: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD\n\nArrowhead will also host two key opinion leader (KOL) webinars on November 18, and November 19, 2020 to discuss data from, and the company’s future plans for, its two investigational cardiometabolic candidates, ARO-APOC3 and ARO-ANG3. The webinars may be accessed on the Events and Presen...